GlobalData on MSN12h
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)
In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of ...